

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | |
|--|---|----|----|--------------------------|--|--------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | | 10/524,355 |
| | | | | Filing Date | | 07/12/2005 |
| | | | | First Named Inventor | | Vicki S. Elliott |
| | | | | Group Art Unit | | Unassigned 1656 |
| | | | | Examiner Name | | Unassigned CARLSON |
| Sheet | 1 | of | 22 | Attorney Docket Number | | 071949-9301 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| ccc | A1 | 5,175,383 | | Leder et al. | December 29, 1992 | |
| | A2 | 5,270,163 | | Gold et al. | December 14, 1993 | |
| | A3 | 5,474,796 | | Brennan | December 12, 1995 | |
| | A4 | 5,605,662 | | Heller et al. | February 25, 1997 | |
| | A5 | 5,686,242 | | Bruice et al. | November 11, 1997 | |
| | A6 | 5,707,618 | | Armentano et al. | January 13, 1998 | |
| | A7 | 5,767,337 | | Roses et al. | June 16, 1998 | |
| | A8 | 5,804,413 | | DeLuca | September 8, 1998 | |
| | A9 | 5,807,522 | | Brown et al. | September 15, 1998 | |
| | A10 | 5,837,458 | | Minshull et al. | November 17, 1998 | |
| | A11 | 5,840,484 | | Seilhamer et al. | November 24, 1998 | |
| | A12 | 5,910,434 | | Rigg et al. | June 8, 1999 | |
| | A13 | 5,914,236 | | Monsma, Jr. et al. | June 22, 1999 | |
| | A14 | 5,932,435 | | Atkins et al. | August 3, 1999 | |
| | A15 | 5,997,848 | | Patton et al. | December 7, 1999 | |
| | A16 | 6,022,691 | | Bruice et al. | February 8, 2000 | |
| jcc | A17 | 6,057,101 | | Nandabalan et al. | May 2, 2000 | |
| | A18 | 6,372,724 | | Pelleg et al. | April 16, 2002 | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|-------------------------------|--------------------------|-------------------------|---------------------|--|---|--|--|----------------|
| Exam iner Initial s* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| see | | B1 | WO95/25116 | | CALIFORNIA INST OF TECHN (US) | 1995-09-21 | | |
| see | | B2 | WO95/35505 | | UNIV LELAND STANFORD JUNIOR (US) | 1995-12-28 | | |
| see | | B3 | WO84/03564 | | COMMW SERUM LAB COMMISSION (AU) | 1984-09-13 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Examiner
Signature

KC Carlson

Date
Considered

6-29-07

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 2 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| pcc | C1 | Aberle, H. et al., "Cadherin-catenin complex: protein interactions and their implications for cadherin function," (1996) <u>J. Cell. Biochem.</u> 61:514-523, (1996) <u>J. Cell. Biochem.</u> 61:514-523 | |
| | C2 | Adam, M.A. and A.D. Miller, "Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions," (1988) <u>J. Virol.</u> 62:3802-3806 | |
| | C3 | Adams et al., "Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation," (1997) <u>J. Clin. Invest.</u> 100:3149-3153 | |
| | C4 | Adams, J.C. et al., "The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development," Tucker (2000) <u>Dev. Dyn.</u> 218:280-299 | |
| | C5 | Altschul, S.F. et al., "Basic local alignment search tool," (1990) <u>J. Mol. Biol.</u> 215:403-410 | |
| | C6 | Anderson, N.L. and J. Seilhamer, "A comparison of selected mRNA and protein abundances in human liver," (1997) <u>Electrophoresis</u> 18:533-537 | |
| | C7 | Antinozzi, P.A. et al., "Metabolic engineering with recombinant adenoviruses," (1999) <u>Annu. Rev. Nutr.</u> 19:511-544 | |
| | C8 | Armentano, D. et al., "Effect of internal viral sequences on the utility of retroviral vectors," (1987) <u>J. Virol.</u> 61:1647-1650 | |
| | C9 | Arndt, G.M. et al., "A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells," (2000) <u>Nucleic Acids Res.</u> 28:E15 | |
| | C10 | Ashkenazi, A. and V.M. Divit, "Apoptosis control by death and decoy receptors," (1999) <u>Curr. Opin. Cell Biol.</u> 11:255-260 | |
| llc | C11 | Auwerx, J., "PPAR γ , the ultimate thrifty gene," (1999) <u>Diabetologia</u> 42:1033-1049 | |

| | | | |
|--------------------|------------|-----------------|---------|
| Examiner Signature | KC Carlson | Date Considered | 6-29-07 |
|--------------------|------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/524,355 |
| | | | | Filing Date | 07/12/2005 |
| | | | | First Named Inventor | Vicki S. Elliott |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 3 | of | 22 | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ² |
| <i>KE</i> | C12 | Baltimore, D., "Intracellular Immunization," (1988) <u>Nature</u> 335:395-396 | | |
| | C13 | Banerji, J. et al., "A gene pair from the human major histocompatibility complex encodes large praline-rich proteins with multiple repeated motifs and a single ubiquitin-like domain," (1990) <u>Proc. Natl. Acad. Sci. USA</u> 87:2374-2378 | | |
| | C14 | Barroso et al., "Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension," (1998) <u>Nature</u> 402:880-883 | | |
| | C15 | Bauer, G. et al., "Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized D34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes," (1997) <u>Blood</u> 89:2259-2267 | | |
| | C16 | Bender, M.A. et al., "Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region," (1987) <u>J. Virol.</u> 61:1639-1646 | | |
| | C17 | Bitter, G.A. et al., "Expression and secretion vectors for yeast," (1987) <u>Methods Enzymol.</u> 153:516-544 | | |
| | C18 | Blaese, R.M. et al., "T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years," (1995) <u>Science</u> 270:475-480 | | |
| | C19 | Blind, M. et al., "Cytoplasmic RNA modulators of an inside-out signal-transduction cascade," (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96:3606-3610 | | |
| | C20 | Boado, R.J. et al., "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," (1998) <u>J. Pharm. Sci.</u> 87:1308-1315 | | |
| <i>plh</i> | C21 | Bolton, A.E. and W.M. Hunter, "The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent," (1973) <u>Biochem. J.</u> 133:529-539 | | |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>H. Carlson</i> | Date Considered | 6-29-07 |
|--------------------|-------------------|-----------------|---------|

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| (use as many sheets as necessary) | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet | 4 | of | 22 |
| | | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| KE | C22 | Bonyhadi, M.L., "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication," (1997) <u>J. Virol.</u> 71:4707-4716 | |
| | C23 | Bordignon, C. et al., "Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients," (1995) <u>Science</u> 270:470-475 | |
| | C24 | Boulay, J.-L. and H. Récipon, "Expression vectors and delivery systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:445-450 | |
| | C25 | Brenner, B. et al., "L-selectin regulates actinpolymerisation via activation of the small G-protein Rac2," (1997) <u>Biochem. Biophys. Res. Commun.</u> 231:802-807 | |
| | C26 | Brody, E.N. and L. Gold, "Aptamers as therapeutic and diagnosis agents," (2000) <u>J. Biotechnol.</u> 74:5-13 | |
| | C27 | Brogie, R. et al., "Light-regulated expression of a pea Ribulose-1,5-Bisphosphate Carboxylase small subunit gene in transformed plant cells," (1984) <u>Science</u> 224:838-843 | |
| | C28 | Brown, D.D. et al., "The thyroid hormone-induced tail resorption program during <i>Xenopus laevis</i> metamorphosis," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:1924-1929 | |
| | C29 | Brummelkamp, T.R. et al., "A system for stable expression of short interfering RNAs in mammalian cells," (2002) <u>Science</u> 296:550-553 | |
| | C30 | Brummendorf et al., "Structure/function relationships of axon-associated adhesion receptors of the immunoglobulin superfamily," (1996) <u>Curr. Opin. Neurobiol.</u> 6:584-593 | |
| | C31 | Buller, R.M. et al., "Decreased virulence of recombinant Vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype," (1985) <u>Nature</u> 317:813-815 | |

| | | | |
|--------------------|---------------------|-----------------|---------|
| Examiner Signature | <i>K.P. Carlson</i> | Date Considered | 6-29-07 |
|--------------------|---------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|--------------------------|------------------|------------------------|-------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/524,355 | | |
| | | Filing Date | 07/12/2005 | | |
| | | First Named Inventor | Vicki S. Elliott | | |
| | | Group Art Unit | Unassigned | | |
| | | Examiner Name | Unassigned | | |
| Sheet | 5 | of | 22 | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| see | C32 | Burge, C. and S. Karlin, "Finding the genes in genomic DNA," (1997) <u>J. Mol. Biol.</u> 268:78-94 | |
| | C33 | Burge, C. and S. Karlin, "Prediction of complete gene structures in human genomic DNA," (1998) <u>Curr. Opin. Struct. Biol.</u> 8:346-354 | |
| | C34 | Burton, D.R., "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:10134-10137 | |
| | C35 | Capecci, M.R., "Altering the genome by homologous recombination," (1989) <u>Science</u> 244:1288-1292 | |
| | C36 | Caruthers, M.H. et al., "New chemical methods for synthesis in polynucleotides," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:215-223 | |
| | C37 | Cavazzana-Calvo, M. et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," (2000) <u>Science</u> 288:669-672 | |
| | C38 | Chang, C.-C. et al., "Evolution of a cytokine using DNA family shuffling," (1999) <u>Nat. Biotechnol.</u> 17:793-797 | |
| | C39 | Chen, L. et al., "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization," (1990) <u>Oncogene</u> 5:1391-1395 | |
| | C40 | Chicz, R.M. and F.Z. Regnier, "High-performance liquid chromatography: effective protein purification by various chromatographic modes," (1990) <u>Methods Enzymol.</u> 182:392-421 | |
| | C41 | Christians, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," (1999) <u>Nat. Biotechnol.</u> 17:259-264 | |
| see | C42 | Chung, T.D., "Characterization of the role of IL-6 in the progression of prostate cancer," (1999) <u>Prostate</u> 15:199-207 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 6-28-07 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 6 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>[Signature]</i> | C43 | Clarke, M.L. et al., "Comparative analysis of artificial antisense RNA regulation in fission yeast and human cells," (2000) <u>Biochem. Biophys. Res. Commun.</u> 268:8-13 | |
| | C44 | Colbere-Garapin, F. et al., "A new dominant hybrid selective marker for higher eukaryotic cells," (1981) <u>J. Mol. Biol.</u> 150:1-14 | |
| | C45 | Cole, S.P. et al., "Human monoclonal antibodies," (1984) <u>Mol. Cell Biol.</u> 62:109-120 | |
| | C46 | Colombatti, A. et al., "The superfamily of proteins with von Willebrand Factor type A-like domains: one theme common to components of extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms," (1991) <u>Blood</u> 77:2305-2315 | |
| | C47 | Coruzzi, G. et al., "Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of rebulose-1,5-bisphosphate carboxylase," (1984) <u>EMBO J.</u> 3:1671-1680 | |
| | C48 | Cote, R.J. et al., "Generation of human monoclonal antibodies reactive with cellular antigene," (1983) <u>Proc. Natl. Acad. Sci. USA</u> 80:2026-2030 | |
| | C49 | Cramer, A. et al., "Improved green fluorescent protein by molecular evolution using DNA shuffling," (1996) <u>Nat. Biotechnol.</u> 14:315-319 | |
| | C50 | Crystal, R.G. et al., "A Phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung," (1995) <u>Hum. Gene Therapy</u> 6:643-666 | |
| | C51 | Crystal, R.G. et al., "Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis," (1995) <u>Hum. Gene Therapy</u> 6:667-703 | |
| <i>[Signature]</i> | C52 | Crystal, R.G., "Transfer of genes to humans: Early lessons and obstacles to success," (1995) <u>Science</u> 270:404-410 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 6-29-07 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 7 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| VCE | C53 | Csete, M.E. et al., "Efficient gene transfer to pancreatic islets mediated by adenoviral vectors," (1995) <u>Transplantation</u> 27:263-268 | |
| | C54 | Cunningham, B.C. and J.A. Wells, "Rational design of receptor-specific variants of human growth hormone," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:3407-3411 | |
| | C55 | Davis, C.G., "The many faces of epidermal growth factor repeats," (1990) <u>New Biol.</u> 5:410-419 | |
| | C56 | de la Fuente, M.A. et al., "CD84 leukocyte antigen is a new member of the Ig superfamily," (1997) <u>Blood</u> 90:2398-2405 | |
| | C57 | Deak, F. et al., "Primary structure and expression of Matrilin-2, the closest relative of cartilage matrix protein within the von Willebrand factor Type A-like module superfamily," (1997) <u>J. Biol. Chem.</u> 272:9268-9274 | |
| | C58 | Dix, K.J., et al., "Comparative Metabolism and Disposition of Gemfibrozil in Male and Female Sprague-Dawley Rats and Syrian golden Hamsters," (1999) <u>Drug Metab. Distrib.</u> 27:138-146 | |
| | C59 | Drickamer, K. et al., "Biology of animal lectins," (1993) <u>Annu. Rev. Cell Biol.</u> 9:237-264 | |
| | C60 | Dryga, S.A. et al., "Identification of mutations in a sindbis virus variant able to establish persistent infection in BHK cells: The importance of a mutation in the nsP2 gene," (1997) <u>Virology</u> 228:74-83 | |
| | C61 | Dull, T. et al., "A third-generation lentivirus vector with a conditional packaging system," (1998) <u>J. Virol.</u> 72:8463-8471 | |
| | C62 | Duplaa, C. et al., "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <u>Anal. Biochem.</u> 212:229-236 | |
| | C63 | Eddy, S.R., "Hidden markov models," (1996) <u>Curr. Opin. Struct. Biol.</u> 6:361-365 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 6-29-01 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| (use as many sheets as necessary) | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet | 8 | of | 22 |
| | | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| <i>KE</i> | C64 | Elbashir, S.M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," (2001) <u>Nature</u> 411:494-498 | |
| | C65 | Engelhard, E.K. et al., The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus," (1994) <u>Proc. Natl. Acad. Sci. USA</u> 91:3224-3227 | |
| | C66 | Faissner, A., "The tenascin gene family in axon growth and guidance," (1997) <u>Cell Tissue Res.</u> 290:331-341 | |
| | C67 | Fawcett, J. et al., "Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes," (1992) <u>Nature</u> 360:481-484 | |
| | C68 | Fields, S. and O. Song, "A novel genetic system to detect protein-protein interactions," (1989) <u>Nature</u> 340:245-246 | |
| | C69 | Fire, A. et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," (1998) <u>Nature</u> 391:806-811 | |
| | C70 | Frick, M.H., et al., "Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia," (1987) <u>New Engl. J. Med.</u> ; 317:1237-1245 | |
| | C71 | Frisch, S.M. et al., "Integrins and anoikis," (1997) <u>Curr. Opin. Cell Biol.</u> 9:701-706 | |
| | C72 | Funatsu, N. et al., "Characterization of a Novel Rat Brain Glycosylphosphatidylinositol-anchored Protein (Kilon), a Member of the IgLON Cell Adhesion Molecule Family," (1999) <u>J. Biol. Chem.</u> 274:8224-8230 | |
| | C73 | Garoff, H. et al., "Recent advances in gene expression using alphavirus vectors," (1998) <u>Curr. Opin. Biotechnol.</u> 9:464-469 | |
| <i>KE</i> | C74 | Gary, S.C. et al., "BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility," (1998) <u>Curr. Opin. Neurobiol.</u> 8:576-581 | |

| | | | |
|--------------------|-----------------|-----------------|---------|
| Examiner Signature | <i>KC Clark</i> | Date Considered | 6-25-07 |
|--------------------|-----------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 9 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>ve</i> | C75 | Gatti, R.A. et al., "Localization of an ataxia-telangiectasia gene to chromosome," (1988) <u>Nature</u> 336:577-580 | |
| | C76 | Goins, W.F. et al., "Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity," (1999; <u>J. Virol.</u> 73:519-532 | |
| | C77 | Gold, L.I. (1999) <u>Crit. Rev. Oncol.</u> 10:303-360 (waiting from SD library) | |
| | C78 | Goldman, C.K. et al., "In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer," (1997) <u>Nat. Biotechnol.</u> 15:462-466 | |
| | C79 | Gossen, M. and H. Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89:5547-5551 | |
| | C80 | Gossen, M. et al., "Transcriptional activation by tetracyclines in mammalian cells," (1995) <u>Science</u> 268:1766-1769 | |
| | C81 | Graham, F.L. and A.J. Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA," (1973) <u>Virology</u> 52:456-467 | |
| | C82 | Gregoire et al., "Understanding adipocyte differentiation," (1998) <u>Physiol. Reviews</u> 78:783-809 | |
| | C83 | Gu, K. et al., "Human dentin phosphophoryn nucleotide and amino acid sequence," (1998) <u>Eur. J. Oral Sci.</u> 106:1043-1047 | |
| | C84 | Gura, T., "A silence that speaks volumes," (2000) <u>Nature</u> 404:804-808 | |
| | C85 | Hadari, Y.R. et al., "Galectin-8; A new rat lectin, related to galectin-4," (1995) <u>J. Biol. Chem.</u> 270:3447-3453 | |
| <i>de</i> | C86 | Haft, D.H. et al., "TIGRFAMs: a protein family resource for the functional identification of proteins," (2001) <u>Nucleic Acids Res.</u> 29:41-43 | |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>KC Carter</i> | Date Considered | 6-25-07 |
|--------------------|------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 10 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| <i>gll</i> | C87 | Hanks, S.K. et al., "Signaling through focal adhesion kinase," (1997) <u>BioEssays</u> 19:137-145 | |
| | C88 | Harrington, J.J. et al., "Formation of de novo centromere and construction of first-generation human artificial microchromosomes," (1997) <u>Nat. Genet.</u> 15:345-355 | |
| | C89 | Harrington, M.G., "Elution of protein from gels," (1990) <u>Methods Enzymol.</u> 182:488-495 | |
| | C90 | Hartman, S.C. and R.C. Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <u>Proc. Natl. Acad. Sci. USA</u> 85:8047-8051 | |
| | C91 | Heller, R.A. et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," (1997) <u>Proc. Natl. Acad. Sci. USA</u> 94:2150-2155 | |
| | C92 | Hidari, K. I. et al., "Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils," (1997) <u>J. Biol. Chem.</u> 272:28750-28756 | |
| | C93 | Higgins, D.G. et al., "CLUSTAL V: Improved software for multiple sequence alignment," (1992) <u>CABIOS</u> 8:189-191 | |
| | C94 | Higgins, D.G. et al., "Fast and sensitive multiple sequence alignments on a microcomputer," (1989) <u>CABIOS</u> 5:151-153 | |
| | C95 | Horn, T. et al., "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for gastric inhibitory polypeptide (GIP)," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:225-232 | |
| | C96 | Howard, A.D. et al., "Orphan G-protein-coupled receptors and natural ligand discovery," (2001) <u>Trends Pharmacol. Sci.</u> 22:132-140 | |
| <i>gll</i> | C97 | Huse, W.D. et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in Phage Lambda," (1989) <u>Science</u> 246:1275-1281 | |

| | | | |
|--------------------|---------------|-----------------|---------|
| Examiner Signature | <i>McCabe</i> | Date Considered | 6-28-07 |
|--------------------|---------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|-------------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 11 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | C98 | Ivics, Z., "Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells," (1997) <u>Cell</u> 91:501-510 | |
| | C99 | Khazaie, K. et al., "EGF receptor in neoplasia and metastasis," (1993) <u>Cancer and Metastasis Rev.</u> 12:255-274 | |
| | C100 | Kimmel, A.R., "Identification and characterization of specific clones: Strategy for confirming the validity of presumptive clones," (1987) <u>Methods Enzymol.</u> 152:507-511 | |
| | C101 | Kobe, B. et al., "Proteins with leucine-rich repeats," (1995) <u>Curr. Opin. Struct. Biol.</u> 5:409-416 | |
| | C102 | Kohda, D. et al., "Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration," (1996) <u>Cell</u> 86:767-775 | |
| | C103 | Kohler, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) <u>Nature</u> 256:495-497 | |
| | C104 | Kozbor, D. et al., "Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas," (1985) <u>J. Immunol. Methods</u> 81:31-42 | |
| | C105 | Kulkarni, N.H. et al., "Characterization and differential expression of a human gene family of olfactomedin-related proteins," (2000) <u>Genet. Res.</u> 76:41-50 | |
| | C106 | Kwok, P.-Y. and Z. Gu, "Single nucleotide polymorphism libraries: why and how are we building them?," (1999) <u>Mol. Med. Today</u> 5:538-543 | |
| | C107 | Lagerstrom, M. et al., "Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA," (1991) <u>PCR Methods Applic.</u> 1:111-119 | |
|  | C108 | Lander, E.S. and D. Botstein, "Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms," (1986) <u>Proc. Natl. Acad. Sci. USA</u> 83:7353-7357 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 6-29-07 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Complete if Known | |
| | | | | Application Number | 10/524,355 |
| (use as many sheets as necessary) | | | | Filing Date | 07/12/2005 |
| | | | | First Named Inventor | Vicki S. Elliott |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 12 | of | 22 | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ² |
| see | C109 | Lasky, L.A., "Lectin cell adhesion molecules (LEC-CAMs): a new family of cell adhesion proteins involved with inflammation," (1991) <u>J. Cell. Biochem.</u> 45:139-146 | | |
| | C110 | Lee, J.-O. et al., "Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18)," (1995) <u>Cell</u> 80:631-638 | | |
| | C111 | Lee, S.W. et al., "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment," (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89:2504-2508 | | |
| | C112 | Letunic, I. et al., "Recent improvements to the SMART domain-based sequence annotation resource," (2002) <u>Nucleic Acids Res.</u> 30:242-244 | | |
| | C113 | Li, W. et al., "Reduced hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta," (2001) <u>Matrix Biol.</u> 19(8):755-60 | | |
| | C114 | Lin, J. et al., "The Phosphatidylinositol 3'-kinase Pathway Is a Dominant Growth Factor-activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells," (1999) <u>Cancer Res.</u> 59:2891-2897 | | |
| | C115 | Liu, X. et al., "Herpes simplex virus mediated gene transfer to primate ocular tissues," (1999) <u>Exp. Eye Res.</u> 169:385-395 | | |
| | C116 | Logan, J. and T. Shenk, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:3655-3659 | | |
| | C117 | Lois, C. et al., "Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors," (2002) <u>Science</u> 295:868-872 | | |
| | C118 | Lowman, H.B. et al., "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen," (1991) <u>J. Biol. Chem.</u> 266:10982-10988 | | |
| see | C119 | Lowy, I. et al., "Isolation of transforming DNA: cloning the hamster apt gene," (1980) <u>Cell</u> 22:817-823 | | |

| | | | |
|--------------------|-----------------|-----------------|---------|
| Examiner Signature | <i>HC Carls</i> | Date Considered | 6-29-07 |
|--------------------|-----------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| (use as many sheets as necessary) | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet | 13 | of | 22 |
| | | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| see | C120 | Lueking, A. et al., "Protein microarrays for gene expression and antibody screening," (1999) <u>Anal. Biochem.</u> 270:103-111 | |
| | C121 | Manda et al., "Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display," (1999) <u>Genomics</u> 51:5-14 | |
| | C122 | Mantovani, A. et al., "Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines," (2001) <u>Trends Immunol.</u> 22:328-336 | |
| | C123 | Marshall, A. and J. Hodgson, "DNA Chips: an array of possibilities," (1998) <u>Nat. Biotechnol.</u> 16:27-31 | |
| | C124 | Marth, J.D., "Recent advances in gene mutagenesis by site-directed recombination," (1996) <u>Clin. Invest.</u> 97:1999-2002 | |
| | C125 | Matthews, D.J. and J.A. Wells, "Engineering an interfacial zinc site to increase hormone-receptor affinity," (1994) <u>Chem. Biol.</u> 1:25-30 | |
| | C126 | Maurer, P. et al., "Extracellular calcium-binding proteins," (1996) <u>Curr. Opin. Cell Biol.</u> 8:609-617 | |
| | C127 | McGregor, D.P. et al., "Spontaneous assembly of bivalent single chain antibody fragments in ESCHERICHIA COLI," (1994) <u>Mol. Immunol.</u> 31:219-226 | |
| | C128 | Melby, P.C. et al., "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) <u>J. Immunol. Methods</u> 159:235-244 | |
| | C129 | Mendoza, L.G. et al., "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)," (1999) <u>Biotechniques</u> 27:778-788 | |
| see | C130 | Mickelson et al., "Differential expression and release of CD54 induced by cytokines," (1995) <u>Hepatology</u> 22:866-875 | |

| | | | |
|--------------------|----------------|-----------------|---------|
| Examiner Signature | <i>HCCarls</i> | Date Considered | 6-28-07 |
|--------------------|----------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/524,355 |
| | | | | Filing Date | 07/12/2005 |
| | | | | First Named Inventor | Vicki S. Elliott |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 14 | of | 22 | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| <i>WEP</i> | C131 | Midwood, K.S., "Elastic Fibers: Building Bridges Between Cells and Their Matrix [Dispatch]," (2002) <u>Current Biology</u> 12:R279-R281 | | |
| | C132 | Miller, A.D., "Progress toward human gene therapy," (1990) <u>Blood</u> 76:271-278 | | |
| | C133 | Miyamoto, S. et al., "Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors," (1996) <u>J. Cell Biol.</u> 135:1633-1642 | | |
| | C134 | Miyata, S. et al., "Expression of the IgLON cell adhesion molecules kilon and OBCAM in hypothalamic magnocellular neurons," (2000) <u>J. Comp. Neurol.</u> 424:74-85 | | |
| | C135 | Montgomery, A.M. et al., "Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3," (1996) <u>J. Cell Biol.</u> 132:475-485 | | |
| | C136 | Morgan, R.A. and W.F. Anderson, "Human gene therapy," (1993) <u>Annu. Rev. Biochem.</u> 62:191-217 | | |
| | C137 | Morris, M.C. et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," (1997) <u>Nucleic Acids Res.</u> 25:2730-2736 | | |
| | C138 | Morrison, S.L. et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 | | |
| | C139 | Muyldermans, S., "Single domain camel antibodies: current status," (2001) <u>J. Biotechnol.</u> 74:277-302 | | |
| | C140 | Nagasawa, A. et al., "Human and mouse ISLR (immunoglobulin superfamily containing leucine-rich repeat) genes: genomic structure and tissue expression," (1999) <u>Genomics</u> 61:37-43 | | |
| <i>WEP</i> | C141 | Nagendra et al., "CD18 integrin and CD54-dependent neutrophil adhesion to cytokine-stimulated human hepatocytes," (1997) <u>Am. J. Physiol.</u> 272:G408-G416 | | |

| | | | |
|--------------------|------------|-----------------|---------|
| Examiner Signature | <i>WEP</i> | Date Considered | 6-29-07 |
|--------------------|------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|--------------------------|------------------|------------------------|-------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/524,355 | | |
| | | Filing Date | 07/12/2005 | | |
| | | First Named Inventor | Vicki S. Elliott | | |
| | | Group Art Unit | Unassigned | | |
| | | Examiner Name | Unassigned | | |
| Sheet | 15 | of | 22 | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>WCE</i> | C142 | Neuberger, M.S. et al., "Recombinant antibodies possessing novel effector functions" (1984) <u>Nature</u> 312:604-608 | |
| | C143 | Neumann, E. et al., "Gene transfer into mouse lyoma cells by electroporation in high electric fields," (1982) <u>EMBO J.</u> 1:841-845 | |
| | C144 | Nowotny, P. et al., "SNP analysis to dissect human traits," (2001) <u>Curr. Opin. Neurobiol.</u> 11:637-641 | |
| | C145 | Nuwaysir, E.F. et al., "Microarrays and toxicology: the advent of toxicogenomics," (1999) <u>Mol. Carcinog.</u> 24:153-159 | |
| | C146 | Oba, K. et al., "Two putative tumor suppressor genes on chromosome 8p may play different roles in prostate cancer," (2001) <u>Cancer Genet. Cytogenet.</u> 124: 20-26 | |
| | C147 | Oleszewski, M. et al., "Implications for L1-L1 homophilic binding," (2000) <u>J. Biol. Chem.</u> 275:34478-34485 | |
| | C148 | Orlandi, R. et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <u>Proc. Natl. Acad. Sci. USA</u> 86:3833-3837 | |
| | C149 | Paddison, P.J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," (2002) <u>Genes Dev.</u> 16:948-958 | |
| | C150 | Paietta, E. et al., "Hodgkin's cell lectin, a lymphocyte adhesion molecule and mitogen," (1989) <u>J. Immunol.</u> 143:2850-2857 | |
| | C151 | Parker, J.D. et al., "Targeted gene walking polymerase chain reaction," (1991) <u>Nucleic Acids Res.</u> 19:3055-3060 | |
| <i>WCE</i> | C152 | Perou, C.M. et al., "Molecular portraits of human breast tumours," (2000) <u>Nature</u> 406:747-752 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>W.C. Carter</i> | Date Considered | 6-25-07 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|-------------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| | | Attorney Docket Number | 071949-9301 |
| (use as many sheets as necessary) | | | |
| Sheet | 16 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| <i>see</i> | C153 | Petersen et al., "Gene therapy expression profiling of advanced lung cancer," (2000) <u>Int J. Cancer</u> , 86:512-517 | |
| | C154 | Poeschla, E. et al., "Development of HIV vectors for anti-HIV gene therapy," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:11395-11399 | |
| | C155 | Ponting, C.P. et al., "A latrophilin/CL-1-like GPS domain in polycystin-1," (1999) <u>Curr. Biol.</u> 9:R585-R588 | |
| | C156 | Putz, T. et al., "Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines," (1999) <u>Cancer Res.</u> 59:227-233 | |
| | C157 | Ranga, U. et al., "Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene," (1997) <u>J. Virol.</u> 71:7020-7029 | |
| | C158 | Ranga, U. et al., "Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:1201-1206 | |
| | C159 | Rao, V.B., "Direct sequencing of polymerase chain reaction-amplified DNA," (1994) <u>Anal. Biochem.</u> 216:1-14 | |
| | C160 | Raper, J.A., "Semaphorins and their receptors in vertebrates and invertebrates," (2000) <u>Curr. Opin. Neurobiol.</u> 10:88-94 | |
| | C161 | Rezniczek, G. A. et al., "Linking integrin $\alpha_6\beta_4$ -based cell adhesion to the intermediate filament cytoskeleton: direct interaction between the β_4 subunit and plectin at multiple molecular sites," (1998) <u>J. Cell Biol.</u> 141:209-225 | |
| <i>see</i> | C162 | Rhodes, C.A., "Transformation of maize by electroporation of embryos," (1995) <u>Methods Mol. Biol.</u> 55:121-131 | |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>H. Carter</i> | Date Considered | 6-28-07 |
|--------------------|------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet | 17 | of | 22 |
| | | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| <i>vee</i> | C163 | Riviere, I. et al., "Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells," (1995) <u>Proc. Natl. Acad. Sci. USA</u> 92:6733-6737 | |
| | C164 | Roberge, J.Y. et al., "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) <u>Science</u> 269:202-204 | |
| | C165 | Rossi, F.M.V. and H.M. Blau, "Recent advances in inducible gene expression systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:451-456 | |
| | C166 | Rossi, J.J., "Therapeutic antisense and ribozymes," (1995) <u>Br. Med. Bull.</u> 51:217-225 | |
| | C167 | Sager, R. et al., "Maspin: A tumor suppressing serpin," (1996) <u>Curr. Top. Microbiol. Immunol.</u> 213:51-64 | |
| | C168 | Sandig, V. et al., "Gene transfer into hepatocytes and human liver tissue by baculovirus vectors," (1996) <u>Hum. Gene Ther.</u> 7:1937-1945 | |
| | C169 | Sarkar, G., "Restriction-site PCR: a direct method of unknown sequence retrieval adjacent to a known locus by using universal primers," (1993) <u>PCR Methods Applic.</u> 2:318-322 | |
| | C170 | Scanlon, K.J. et al., "Oligonucleotide-mediated modulation of mammalian gene expression," (1995) <u>FASEB J.</u> 9:1288-1296 | |
| | C171 | Scharf, D. et al., "Heat stress promoters and transcription factors," (1994) <u>Results Probl. Cell Differ.</u> 20:125-162 | |
| | C172 | Schena, M. et al., "Parallel human genome analysis: microarray-based expression monitoring of 1000 genes," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:10614-10619 | |
| <i>vee</i> | C173 | Schena, M. et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," (1995) <u>Science</u> 270:467-470 | |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>H. Clarke</i> | Date Considered | 6-29-07 |
|--------------------|------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|-------------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| (use as many sheets as necessary) | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| Sheet | 18 | of | 22 |
| | | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ve | C174 | Schultz, J. et al., "SAM as a protein interaction domain involved in developmental regulation," (1997) <u>Protein Sci.</u> 6:249-253 | |
| | C175 | Schultz, J. et al., "SMART, a simple modular architecture research tool: Identification of signaling domains," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:5857-5864 | |
| | C176 | Schwarze, S.R. et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse," (1999) <u>Science</u> 285:1569-1572 | |
| | C177 | Scorer, C.A. et al., "Rapid selection using G418 of high copy number transformants of Pichia Pastoris for high-level foreign gene expression," (1994) <u>Bio/Technology</u> 12:181-184 | |
| | C178 | Shalon, D. et al., "A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization," (1996) <u>Genome Res.</u> 6:639-645 | |
| | C179 | Skerra, A., "Anticalins: A new class of engineered ligand-binding proteins with antibody-like properties," (2001) <u>J. Biotechnol.</u> 74:257-275 | |
| | C180 | Slater, J.E., "Environmental and occupational disorders," et al. (1998) <u>J. Allergy Clin. Immunol.</u> 102:469-475 | |
| | C181 | Steiner, S. and N.L. Anderson, "Expression profiling in toxicology—potentials and limitations," (2000) <u>Toxicol. Lett.</u> 112-113:467-471 | |
| | C182 | Su, L., "Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro," (1997) <u>Blood</u> 89:2283-2290 | |
| ve | C183 | Su, Z.-Z. et al., "Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:7252-7257 | |

| | | | |
|---------------------------|-------------------|------------------------|---------|
| Examiner Signature | <i>KC Carlson</i> | Date Considered | 6-29-07 |
|---------------------------|-------------------|------------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--|---|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number | 10/524,355 07/12/2005 Vicki S. Elliott Unassigned Unassigned 071949-9301 |
| Sheet | 19 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>See</i> | C184 | Suzuki et al., "Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones," (2000) <u>Jpn. J. Pharmacol.</u> 84:113-123 | |
| | C185 | Suzuki, S.T., "Protocadherins and diversity of the cadherin superfamily," (1996) <u>J. Cell Sci.</u> 109:2609-2611 | |
| | C186 | Takamatsu, N., "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TRV-RNA," (1987) <u>EMBO J.</u> 6:307-311 | |
| | C187 | Takeda, S., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," et al. (1985) <u>Nature</u> 314:452-454 | |
| | C188 | Taylor, "Using genetic variation to study human disease," (1999) <u>Cell</u> 97:9-12 | |
| | C189 | Taylor, J.G. et al., "Deconstructing type 2 diabetes," (2001) <u>Trends Mol. Med.</u> 7:507-512 | |
| | C190 | Taylor, P.C. et al., "Immunotherapy for rheumatoid arthritis," (2001) <u>Curr. Opin. Immunol.</u> 13:611-616 | |
| | C191 | Theopold, U. et al., "Helix pomatia lectin, an inducer of Drosophila immune response, binds to Hemomucin, a novel surface mucin," (1996) <u>J. Biol. Chem.</u> 271:12708-12715 | |
| | C192 | Thomas, B.F., et al., "Isolation and identification of novel metabolites of gemfibrozil in rat urine," (1999) <u>Drug Metab. Distrib.</u> 27:147-157 | |
| | C193 | Thomson, J.A. et al., "Embryonic stem cell lines derived from human blastocysts," (1998) <u>Science</u> 282:1145-1147 | |
| <i>See</i> | C194 | Toribara, N.W. et al., "Human gastric mucin. Identification of a unique species by expression cloning," (1993) <u>J. Biol. Chem.</u> 268:5879-5885 | |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>K. Carter</i> | Date Considered | 6-28-07 |
|--------------------|------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.



⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|----|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | |
| | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| | | Attorney Docket Number | 071949-9301 |
| Sheet | 20 | of | 22 |

(use as many sheets as necessary)

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | C195 | Toribara, N.W. et al., "The carboxyl-terminal sequence of the human secretory Mucin, MUC6. Analysis of the primary amino acid sequence," (1997) <u>J. Biol. Chem.</u> 272:16398-16403 | |
| | C196 | Tran, H. et al., "The self-association and fibronectin-binding sites of fibulin-1 map to calcium-binding epidermal growth factor-like domains," (1997) <u>J. Biol. Chem.</u> 272:22600-22606 | |
| | C197 | Trask, B.J., "Fluorescence in situ hybridization," (1991) <u>Trends Genet.</u> 7:149-154 | |
| | C198 | Triglia, T. et al., "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," (1988) <u>Nucleic Acids Res.</u> 16:8186 | |
| | C199 | Uckert, W. and W. Walther (1994) <u>Pharmacol. Ther.</u> 63:323-347 | |
| | C200 | Ulrix, W. et al., "The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells," (1999) <u>FEBS Lett</u> 455:23-26 | |
| | C201 | Uyemura, K. et al., "Cell-adhesion proteins of the immunoglobulin superfamily in the nervous system," (1996) <u>Essays Biochem.</u> 31:37-48 | |
| | C202 | Van Heeke, G. and S.M. Schuster, "Expression of human synthetase in Escherichia coli," (1989) <u>J. Biol. Chem.</u> 264:5503-5509 | |
| | C203 | Verma, I.M. and N. Somia, "Gene therapy - promises, problems and prospects," (1997) <u>Nature</u> 18:389:239-242 | |
| | C204 | Wagner, K.U. et al., "Cre-mediated gene deletion in the mammary gland," (1997) <u>Nucleic Acids Res.</u> 25:4323-4330 | |
|  | C205 | Wahl, G.M. and S.L. Berger, "Molecular hybridization of immobilized nucleic acids: theoretical concepts and practical considerations," (1987) <u>Methods Enzymol.</u> 152:399-407 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 6-29-07 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|------------|--------------------------|------------------|------------------------|-------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/524,355 | | |
| | | Filing Date | 07/12/2005 | | |
| | | First Named Inventor | Vicki S. Elliott | | |
| | | Group Art Unit | Unassigned | | |
| Examiner Name | Unassigned | | | | |
| Sheet | 21 | of | 22 | Attorney Docket Number | 071949-9301 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|  | C206 | Wang et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," (2000) <u>Oncogene</u> 19:1519-1528 | |
| | C207 | Way et al., "Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues," (2001) <u>Endocrinology</u> 142:1269-1277 | |
| | C208 | Weiss, G.A. and H.B. Lowman, "Anticalins versus antibodies: made-to-order binding proteins for small molecules," (2000) <u>Chem. Biol.</u> 7:R177-R184 | |
| | C209 | Wigler, M. et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) <u>Cell</u> 11:223-232 | |
| | C210 | Wigler, M. et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <u>Proc. Natl. Acad. Sci. USA</u> 77:3567-3570 | |
| | C211 | Winter, G. et al., "Man-made antibodies," (1991) <u>Nature</u> 349:293-299 | |
| | C212 | Winter, J. et al., "The expression of heat shock protein and cognate genes during plant development," (1991) <u>Results Probl. Cell Differ.</u> 17:85-105 | |
| | C213 | Wise, A. et al., "Target validation of G-protein coupled receptors," (2002) <u>Drug Discovery Today</u> 7:235-246 | |
| | C214 | Wistuba, I.I. et al., "Comparison of features of human breast cancer cell lines and their corresponding tumors," (1998) <u>Clin. Cancer Res.</u> 4:2931-2938 | |
| | C215 | Xu, H. et al., "Viral transduction of trkA into cultured nodose and spinal motor neurons conveys NGF responsiveness," (1994) <u>Dev. Biol.</u> 163:152-161 | |
|  | 6248 | Yang, Y. et al., "The structural basis of ankyrin-like repeat function as revealed by the solution structure of myotrophin," (1998) <u>Structure</u> 6:619-626 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 6-28-07 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|----|--------------------------|------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/524,355 |
| | | Filing Date | 07/12/2005 |
| | | First Named Inventor | Vicki S. Elliott |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (use as many sheets as necessary) | | Attorney Docket Number | 071949-9301 |
| Sheet | 22 | of | 22 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| HCE | C217 | Yao, I. et al., "Synamon, a Novel Neuronal Protein Interacting with Synapse-associated Protein 90/Postsynaptic Density-95-associated Protein," (1999) <u>J. Biol. Chem.</u> 274: 27463-27466 | |
| | C218 | Yu, M. et al., "A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1," (1993) <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 | |
| | C219 | Zabner, J. et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in masal epithelia of patients with cystic fibrosis," (1993) <u>Cell</u> 75:207-216 | |
| | C220 | Zhou, Z. et al., "Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors," (1998) <u>Int. J. Cancer</u> 78:95-99 | |
| | C221 | Zitzer, H. et al., "Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain," (1999) <u>J. Biol. Chem.</u> 274:32997-33001 | |
| ICL | C222 | Zufferey, R. et al., "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery," (1998) <u>J. Virol.</u> 72:9873-9880 | |

| | | | |
|--------------------|------------|-----------------|---------|
| Examiner Signature | <i>HCE</i> | Date Considered | 6-29-07 |
|--------------------|------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.